STOCK TITAN
  1. Home
  2. News
  3. HYPR

Hyperfine, Inc. Class A - HYPR STOCK NEWS

Welcome to our dedicated news page for Hyperfine Class A (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on Hyperfine Class A .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hyperfine Class A 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hyperfine Class A 's position in the market.

News
Hyperfine, Inc. to Announce First Quarter 2024 Financial Results on May 13, 2024
Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) will announce its first quarter 2024 financial results on May 13, 2024. The company, known for its FDA-cleared portable MR brain imaging system, the Swoop® system, will host a conference call on the same day. The event can be accessed via the Investors page of Hyperfine, Inc.'s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
Rhea-AI Summary
Hyperfine, Inc. (HYPR) presented seventeen abstracts at the ISMRM annual meeting showcasing the potential of their portable MR imaging system, Swoop®, in aiding physicians with screening and monitoring for Alzheimer’s and multiple sclerosis biomarkers. The company aims to revolutionize brain imaging with their FDA-cleared technology, demonstrating its effectiveness across various clinical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
News
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) enrolls first Alzheimer's patients in CARE PMR study to assess the clinical utility of Swoop® Portable MR Imaging® system in detecting ARIA events in patients receiving amyloid-targeting therapy. The study aims to simplify workflow and improve care efficiency in Alzheimer's treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
none
News
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Hyperfine, Inc. (HYPR) reported strong growth in 2023, achieving $11.03 million in revenues, up 62% from 2022. The company sold 37 Swoop® systems in 2023, with a net loss of $44.24 million. Hyperfine received multiple certifications, launched new programs, and reduced cash burn to extend cash runway. Fourth quarter 2023 revenues were $2.69 million, up 89% from the previous year. The company sold seven Swoop® systems in Q4 2023, with a net loss of $10.68 million. Management expects 2024 revenue to reach $12 to $15 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
earnings
-
News
Hyperfine, Inc. Collaborates with King’s College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal
Rhea-AI Summary
Hyperfine, Inc. (HYPR) showcases the first FDA-cleared portable MR brain imaging system to The Princess Royal, highlighting its use in testing MR access disparities in low- and medium-resource countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
none
-
News
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024
Rhea-AI Summary
Hyperfine, Inc. (HYPR) will report financial results for Q4 and full year 2023 on March 21, 2024. The company, known for its portable MR brain imaging system, Swoop®, has redefined brain imaging technology. The conference call will be hosted by management at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live webcast on Hyperfine's Investors page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference
Rhea-AI Summary
Hyperfine, Inc. (HYPR) to present at Oppenheimer Healthcare MedTech & Services Conference with a focus on their FDA-cleared portable MR brain imaging system, the Swoop® system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
News
Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes
Rhea-AI Summary
Hyperfine, Inc. (HYPR) collaborates with Athletic Heart to provide portable brain imaging screenings to professional athletes, starting with retired basketball players. The partnership aims to enhance brain health insights for athletes through the use of the Swoop® Portable MR Imaging® system. The inaugural event took place at the 2024 All-Star game in Indianapolis, showcasing the commitment to accessible and comprehensive medical care for athletes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
News
Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announced the presentation of four abstracts at the 2024 International Stroke Conference, showcasing the clinical utility and applications of portable ultra-low-field MR imaging. The Swoop® system aims to transform the diagnosis and treatment of acute ischemic stroke. The company also provided an update on the enrollment progress of the ACTION PMR study, which aims to integrate brain imaging with the Swoop® system into the stroke diagnosis and treatment workflow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
News
Hyperfine, Inc. Launches AI-powered Brain Imaging Software for Enhanced Image Quality and Ease of Use
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) has obtained CE and UKCA approval for the eighth generation of Swoop® system software, which includes AI-powered features such as DWI denoising. The software has been well-received by users, improving image quality and workflow efficiencies. With international certifications, the company is poised for global expansion, aiming to bring the Swoop® system to a broader market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
AI
Stock HYPR logo
Hyperfine, Inc. Class A

Nasdaq:HYPR

HYPR Rankings

#4636 Ranked by Market Cap
#690 Ranked by Stock Gains
N/A Ranked by Dividends

HYPR Stock Data

58.28M
51.21M
11.94%
26.6%
1.79%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States of America
GUILFORD

About HYPR

hyperfine’s mission is to make mri accessible to every patient, regardless of income or resources. anytime. anywhere.hyperfine’s swoop® portable mr imaging system™ addresses limitations of current imaging technologies. swoop wheels directly to a patient’s bedside, where it plugs into a standard electrical outlet and uses an apple ipad® for control. images display within minutes, enabling critical decision-making capabilities across various clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. designed as a complementary system to fixed conventional mri systems, new users can be trained on system operation, device navigation, and safety in about 30 minutes, helping clinicians streamline workflow. the complete swoop™ portable mr imaging system costs less than the annual service contract for most fixed conventional mri systems.in august 2020, swoop received market-ready fda clearance for portable mr imaging of the brain and head for patients of